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Introduction
The importance of the Fibroblast Growth Factor (FGF) receptor 3 
(FGFR3) signalling pathway in endochondral bone development, and 
more specifically in the regulation of chondrocyte proliferation and 
differentiation in the epiphyseal growth plate, was discovered when an 
activating mutation in FGFR3 was found to cause achondroplasia, the 
common form of human dwarfism [1]. Even though the mechanism of 
action of these mutations is not fully understood, pathways involved 
in FGFR3 signalling such as the STAT and Mitogen Activating 
Protein Kinase (MAPK) pathways have been suggested to play a role 
[2-4]. Inhibition of chondrocyte proliferation is caused by induced 
phosphorylation of STAT-1, which after translocation into the 
nucleus induces transcription of cell cycle inhibitors such as p21 [5]. 
In addition, the MAPK-pathway has been suggested to play a role 
due to phosphorylation of Erk1/2 and p38 [6-8]. The latter may cause 
premature and enhanced osteoblast differentiation of cells carrying 
activating mutations in FGFR3. This was confirmed in a study by Su 
et al., where enhanced phosphorylation of Erk-1/2 was suggested to 
be responsible for elevated cell proliferation together with impaired 
bone matrix mineralisation [9]. Phosphorylation of p38 in the same 
study was correlated to promotion of osteogenic differentiation but 
reduction in proliferation and cell induced mineralisation.
The location of the mutation may be crucial for the severity of 
resulting skeletal dysplasia. The most common mutation, present 
in 98% of the cases of achondroplasia, is the G380R substitution in 
the transmembrane domain [10]. This causes increased stabilisation 
and accumulation at the cell surface thus promoting uncontrolled, 
prolonged, ligand-dependent activation of the receptor. Another 
common activating mutation in FGFR3 is the N540K mutation, detected 
in 60-65% of patients diagnosed with the less severe hypochondroplasia. 
This mutation is located in the intracellular Tyrosine Kinase (TK)-1 
domain of the receptor [11], and has therefore been suggested to give 
an altered gene-expression pattern compared to mutations in other 
domains, such as the transmembrane domain. In addition, the N540K 
mutation displays a ligand-independent phosphorylation of the TK 
domain, leading to activation of the receptor in absence of a binding 
ligand. 
To assess the influence of FGFR3 mediated signalling on bone 
progenitors, we herein analyse Periosteal Derived Cells (PDC) isolated 
from patients with achondroplasia and hypochondroplasia in vitro 
and in vivo. Together with high proliferative and osteochondrogenic 
differentiation profiles in these cells [12,13], the location of the periost 
suggests these cells to be early contributors in fracture repair and 
are therefore deemed to mediate the primary steps of ossification in 
the fracture haematoma [14,15]. We herein demonstrate that cells 
containing the N540K mutation display increased proliferation and 
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Abstract
Activating mutations in Fibroblast Growth Factor Receptor 3 (FGFR3) have previously been shown to cause 
skeletal dysplasias through their effect on growth plate chondrocytes. However, the effect of FGFR3 mutations on 
bone progenitor cells may differ. The objective of this study was to investigate the effect of specific activating FGFR3 
mutations on ectopic in vivo bone formation by periosteal derived cells (PDCs) seeded on calcium phosphate/
collagen scaffolds. 
PDCs were isolated from hypochondroplasic (N540K mutation) and achondroplasic (G380R mutation) 
patients, along with age/sex matched controls. These cells were characterised in vitro for proliferation, osteogenic 
differentiation, FGFR3 signalling and in vivo bone formation. Subsequently, empirical modelling was used to find 
correlations between in vivo formed bone and in vitro cell behaviour. These data showed that in contrast to the G380R 
mutation, which produced no bone, the N540K mutation induced significant ectopic bone formation on specific 
carriers. This allowed correlation between percentage of induced bone formation to elevated in vitro proliferation 
and differentiation. Correlating osteogenic markers included Collagen type 1, alkaline phosphatase and osteocalcin. 
Enhanced proliferation was attributed to increased phosphorylation of Erk-1/2. 
This study highlights the importance of FGFR3 in periosteal cell differentiation and also indicates it potential for 
targeted tissue engineering strategies.
Citation: Bolander J, Roberts SJ, Eyckmans J, Geris L, Luyten FP (2012) The Effect of Activating FGFR3 Mutations on Osteogenic Differentiation and 
Ectopic Bone Formation. J Tissue Sci Eng S2:003. doi:10.4172/2157-7552.S2-003
Page 2 of 5
  J Tissue Sci Eng        Cartilage and Bone Tissue Engineering                        ISSN:2157-7552 JTSE an open access journal 
enhanced osteogenic differentiation, which could be correlated to in 
vivo bone formation.
This work represents a first step to elucidate the effect of FGFR3 
signalling on PDC dynamics and bone formation.
Materials and Methods
Isolation of periosteal derived cells
Isolation of PDCs from four donors as follows; N540K: 5 year old 
male, G380R: 5 year old male, Control 1: 3 year old female, Control 
2: 8 year old male, was carried out as described by De Bari et al. [12]. 
Cells were expanded in growth medium (GM) consisting of Dulbecco’s 
Modified medium (DMEM, Invitrogen, Merelbeke, Belgium) 
supplemented with 10% FBS (Gibco, Merelbeke, Belgium) and 
antibiotic-antimycotic solution (100 units/ml penicillin, 100 mg/ml 
streptomycin, and 0.25 mg/ml amphotericin B; Invitrogen, Merelbeke, 
Belgium) until passage 5. The ethical committee for Human Medical 
Research (KU Leuven) approved all procedures and the patient 
informed consents were obtained.
Analysis of cell metabolism and FGFR3 signalling
Metabolic activity was measured by incubation of monolayer 
cultures with 10% Alamar Blue® (Invitrogen, Merelbeke, Belgium) 
in GM. Fluorescent signal was measured and values from each time 
point were normalised to day 1 for respective cell population. FGFR3 
signalling was analysed within in vitro cultured proliferating cells 
by Western blot. Briefly, the cells were lysed in protein extraction 
buffer containing 0.3 M PMSF and Protease Inhibition Cocktail 
(Sigma, Bornem, Belgium). Protein concentration was determined 
using the PierceTM BCA Protein Assay Kit (Thermo SCIENTIFIC, 
Erembodegem, Belgium) and 10 µg was loaded on NuPAGE 4-12% 
Bis-Tris gel (Invitrogen, Merelbeke, Belgium). Antibodies were 
diluted according to the manufacturer`s instructions: Phospho-STAT1 
(Tyr701 (58D6)) rabbit monoclonal, Phospho-p38 rabbit monoclonal 
(Thr180/Tyr182), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
(E10) mouse monoclonal (Cell Signalling Technology). GAPDH was 
used to assess equal loading of proteins, images were developed by a 
LAS3000 Imaging System (FUJI). 
Osteogenic differentiation
To analyse the differentiation capabilities of isolated cells, 
monolayer cultures were stimulated for 21 days with osteogenic media 
(OM; GM containing 100 nM dexamethasone, 0.25 mM ascorbic acid 
and 10 mM β-Glycero Phosphate). As control, cells were cultured 
in parallel in GM. RNA extraction was performed using the RNeasy 
Kit (Qiagen, Venlo, Netherlands) according to the manufacturer`s 
instructions. Complementary DNA (cDNA) was obtained by reverse 
transcription of 500 ng total RNA with Oligo (dT) primer (Superscript 
III; Invitrogen, Merelbeke, Belgium). Quantitative PCR was performed 
using a Rotor-Gene 6000 system (Corbett, Westburg, Leusden, and The 
Netherlands) with a SybrGreen detection system (Applied Biosystems, 
Halle, Belgium). The two step reaction, 94°C for 3 s and 60°C for 40 s, 
was cycled 40 times and relative gene expression calculated using the 
calculated 2-ΔΔCT method.
In vivo osteogenesis
To analyse the bone forming potential of cell populations, two 
different clinically used bone void fillers, composed of calcium 
phosphate (CaP) [16] particles in an open collagen network (CopiOsTM 
(Zimmer, Wemmel, Belgium) and CollagraftTM (Neucoll, Cambell, 
California, US)), were selected based on their different properties and 
bone forming capacity in combination with hPDCs [17]. Each material 
was punched into 21 mm3 cylindrical scaffolds. 1 million cells applied 
to the upper surface of each scaffold. Seeded scaffolds were incubated 
overnight at 37°C to allow cell attachment, and thereafter implanted 
subcutaneously in the back at the cervical region of NMRI-nu/nu mice. 
Implants were collected 56 days post implantation, each scaffold was 
fixed in 4% formaldehyde, decalcified in EDTA/PBS (pH 7.5) for 2 
weeks, paraffin embedded and processed for histology. All procedures 
were approved by the local ethical committee for Animal Research 
(KU Leuven). Histological examination and bone quantification were 
carried out as previously described [17].
Multivariate analysis and partial least-squares regression 
modelling
In a multivariate analysis pairwise correlations between all 
variables from in vitro and in vivo measurements were investigated 
using the Pearson product-moment correlations for each pair of 
variables. Correlations were calculated by pairwise deletion method 
and significant probabilities were identified for p-values < 0.05.
In order to determine whether multiple molecular signals in 
combination could quantitatively predict the in vivo bone formation 
response of different cell types, a mathematical formalism, partial-least 
square regression (PLSR), previously shown to be capable of relating 
quantitative contributions of multiple signals to a (single) measured 
response [18,19], was used. PLSR is able to identify the information 
content within the set of measured molecular signals that most 
closely maps onto the output response (amount of bone formation). 
The resulting mapping of lumped signals to corresponding responses 
allows to identify the most “important variables” for the in vivo bone 
formation by hPDCs in CopiosTM and CollagraftTM carriers. Each 
cell population was individually withheld from the training set to 
construct a cross-validation model to minimise the risk of over fitting. 
To perform the Multivariate Analysis, correlation clustering and to 
generate the PLSR model, the software package JMP® 8 (SAS Institute 
Inc., Cary, NC) was used. 
Statistical analysis
Data expressed as mean ± SEM. Statistical significance was 
determined using student T-test to compare between independent 
groups. Statistical significance is indicated on all graphs as follows: *: p 
< 0.05, **: p < 0.01, ***: p < 0.001 (n=3).
Results
Activating FGFR3 mutation increases periosteal cell 
proliferation
Metabolic activity was measured as an indication of cell proliferation 
on cells containing an activating mutation in the transmembrane- and 
the TK1-domain of FGFR3; G380R and N540K respectively along with 
controls. As seen in Figure 1A, cells commonly keep a linear growth 
until day 11, the time point when cells reach confluence. N540K cells 
displayed highest metabolic activity until day 11, the G380R mutant 
displayed a similar metabolic profile as its age-matched control, 
Control 2. 
To investigate whether FGFR3 signalling was associated with 
alteration in cell proliferation observed in N540K mutant cells, 
phosphorylation status of FGFR3 signalling proteins was analysed 
(Figure 1B), where phosphorylation of STAT1 was similar in all four 
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cell populations. The MAPK-pathway member p38 is a known inducer 
of cell differentiation. Both FGFR3 mutants N540K and G380R 
displayed an elevated phosphorylation of p38 when compared to 
control cell populations. However, only N540K displayed high levels 
of phosphorylated Erk1/2, a MAPK associated with cell proliferation. 
Increased osteogenic differentiation with the N540K 
mutation
The effect of FGFR3 mutations on osteogenic differentiation of 
PDCs was investigated by gene expression of bone markers such as 
Sox9, Runx2, alkaline phosphatase (ALP), collagen type 1 (Coll1) and 
osteocalcin. A significant induction in the expression of FGFR3 was 
observed in N540K cells during osteogenic differentiation together 
with the G380R cells (Figure 2A). No induction in FGFR3 expression 
was observed in control cell populations. 
Osteogenic stimulated cells from all cell populations displayed a 
significant decrease in expression of a chondrogenic transcription 
factor, Sox9 (Figure 2B). Conversely, the osteogenic marker Runx2 
was significantly up regulated in N540K, G380R and control 2 (Figure 
2C). Expression of the early osteoblast marker ALP was significantly 
increased in all cell populations when stimulated with OM, and the 
elevation was a 5 fold higher in the N540K mutant (Figure 2D). Coll1, 
an early/mid marker of osteogenic differentiation, showed elevated 
expression levels in stimulated N540K mutant and Control 2 as 
compared to unstimulated cells. In contrast, expression of Coll1 in the 
G380R mutant and control 1 was down regulated in stimulated cells 
(Figure 2D). Expression of the late osteogenic marker, osteocalcin, 
increased 1.6 fold in stimulated N540K cells. G380R, control 1 and 
control 2 displayed minor changes in expression, in comparison to 
unstimulated cells. 
Activating FGFR3 mutations affect the ectopic bone forming 
capacity of periosteal cells 
To investigate the speciﬁc effect on ectopic in vivo bone forming 
capacity between the two mutants N540K and G380R, and control 
populations, cells were seeded on two different CaP-carriers with either 
known bone forming capacity (CollagraftTM) or poor bone forming 
capacity (CopiOsTM) in combination with hPDCs. Histomorphometry 
revealed that a range in quantity of de novo formed bone was observed 
in combination of both carriers and cell populations (Figure 3). 
N540K, control 1 and control 2 could be observed to induce ectopic 
bone formation within the CopiOsTM material. The amounts of bone 
were quantified to (Figure 3A-3D, 3I): Control 1: 0,03±0,017%, Control 
2: 2,11±0,51%, N540K: 31,5±2,5%, G380R: 0±0%. When cells were 
seeded on the CollagraftTM carrier, all cell population displayed the 
ability to form bone to various extents as (Figure 3E-3H, 3I): Control 
1: 0,44±0,024%, Control 2: 3,89±0,50%, N540K: 15,13±1,75%, G380R: 
0,57±0,19%. The N540K mutation results in a significant increase in 
bone formation of 15 fold in CopiOsTM and 3.8 fold in CollagraftTM 
when compared to its control. Upon analysis of H&E stained sections 
bone spicules could be seen in sections with de novo formed bone. 
Prediction of in vivo results by in vitro measurements 
In Figure 4A the in vitro and in vivo measurements are clustered 
according to their pairwise correlations. Correlation between amount 
of bone formation in both scaffolds and phosphorylation of ERK1/2 and 
p38 together with expression of FGFR3, p21 and Sox9 are significant 
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Figure 1: Metabolic activity and affected signalling pathways. A, 
Metabolic activity was measured where FGFR3 mutant N540K displayed 
highest metabolic activity until day 11. The G380R mutant displays a similar 
profile as its matched control, control 2. All cell populations keep a growth 
curve until day 11 when confluence is reached. B, Signalling pathways 
affected by FGFR3 mutants indicate similar phosphorylation of STAT-1 in all 
cell populations. Signalling through MAPK-pathway members display elevated 
phosphorylation of Erk-1/2 in both mutants, significant activation in N540K. 
Induced phosphorylation of p38 was displayed in both N540K and G380R 
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Figure 2: Gene expression analysis of MAPK target genes and osteogenic 
markers. Gene expression of FGFR3 display a significant elevated expression 
in N540K cells stimulated with OM compared to unstimulated cells. Decreased 
Sox9 expression in all cell populations indicate that cells are not in the 
chondrogenic lineage, confirmed by Runx2 which is significantly increased 
in osteogenic stimulated cells carrying N540K and G380R mutations. The 
early osteogenic marker ALP displays a significant increased expression in 
all stimulated cell populations, however, the increase is over a 5-fold in the 
N540K mutant and a 3-fold in the G380R mutant. An increase in the mid and 
late osteogenic markers Coll1 and OCN can be seen in the N540K mutant. 
Copios(BV%)–pERK1/2: p=0.0374, p38–FGFR3: p=0.0222, p38–p21: 
p=0.0390, p38–Sox9: p=0.0276).
The variable importance plot (Figure 4B) generated by a first PLSR 
model including all in vitro measurements indicates that only six out 
of the 11 variables are important to obtain a good prediction. Variables 
with an importance larger than 0.8 have been retained for the second 
PLSR model. In the final model, a combination of five molecular 
signals (ALP, Coll1, osteocalcin, pERK1/2 and Metabolic Activity Day 
6, all with a positive effect on the predicted amount of in vivo bone 
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formation) is capable of predicting the quantity of bone formed in vivo 
with an accuracy of 93.56% for one principal component (Figure 4C).
Discussion
Activating mutations in FGFR3 may cause short limb bud 
formation, which can result in disorders like achondroplasia and 
hypochondroplasia due to impaired chondrogenesis [10,11]. In this 
study, we investigated the effect of specific mutations on periosteal cell 
dynamics. This was carried out by analysing metabolic activity, affected 
signalling pathways and in vivo ectopic bone formation.
Upon investigation of metabolic activity, previously used as a 
measure of cell proliferation [20], cells carrying the N540K mutation 
displayed a high profile within the cultures until day 11. The increased 
metabolic activity in the N540K mutant, when compared to all other 
cell populations, appears to be the opposite of what has previously been 
shown in activating FGFR3 mutants in the growth plate in vivo [6]. 
This result may be due to the fact that we are working with a progenitor 
cell population and not differentiating chondrocytes, seen in the in 
vivo growth plate where activating FGFR3 mutations mainly affect 
proliferating and differentiating chondrocytes. Additionally, recent 
work on bone marrow stromal cells, which may reflect PDC biology 
better than chondrocytes, suggest that activating mutations in the 
transmembrane domain result in a decreased cell proliferation, which 
is partially reflected in our data in G380R [9]. To our knowledge no 
data is available on the effect of the N540K mutation, but due to the 
altered mechanism of ligand independent activation, this mutant may 
indeed function differently compared to transmembrane mutations. To 
identify whether FGFR3 signalling was causing the altered proliferative 
profile, activation of downstream FGFR3 signalling modulators was 
investigated. Phosphorylation of STAT1 has previously been suggested 
a role in inhibition of chondrocyte proliferation [21], the lack of 
difference in protein activation may explain the failure to observe 
a decreased proliferation when comparing the FGFR3 mutant cell 
populations with controls. N540K and G380R mutants induce activation 
of p38, which has previously been shown to allow the promotion of 
osteogenic differentiation [9]. Additionally, N540K showed enhanced 
phosphorylation of Erk1/2, which has been implicated in the induction 
of cellular proliferation [9], and may indicate why this mutation is 
associated with a higher proliferative capacity of PDCs in vitro under 
the experimental conditions used.
To investigate the osteogenic potential of the studied cell 
types, osteogenic marker expression was analysed in populations 
of unstimulated and osteogenic stimulated cells. An enhanced 
expression of FGFR3 mRNA transcripts was observed in stimulated 
cells in both FGFR3 mutant populations, in line with literature [22]. 
This can be correlated to work by Matsushita et al. [8] that reported 
an elevated expression of FGFR3 in chondrocytes with an activating 
mutation in FGFR3. This led to premature synchondrosis closure and 
increased osteoblast differentiation in areas surrounding the closure. 
Interestingly, this was associated with increased bone formation [8]. 
This is especially remarkable as the N540K mutant induced significant 
in vivo ectopic bone formation in combination with CaP-carriers in 
this study. 
Sox9 is expressed in proliferating and differentiating chondrocytes 
until the final stage of hypertrophy is reached and is therefore a marker 
which provide an indication whether cells are in the chondrogenic 
lineage [23]. Therefore, the decrease in Sox9 expression observed in 
osteogenic stimulated cells indicates that the cells are not entering the 
chondrogenic lineage [24,25]. This is confirmed by Runx2 expression, 
as Runx2 is known to promote differentiation into the mature 
osteoblast and then further into the osteocyte termination [26,27]. 
The expression of Runx2 is enhanced in both FGFR3 mutants cultured 
in conditions promoting osteogenesis, compared to unstimulated 
cells. The expression is highest in N540K, and leads to the hypothesis 
that this mutation allows an increased susceptibility for osteogenic 
differentiation. This hypothesis is strengthened by the increased 
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Figure 3: Analysis on ectopic bone formation in vivo. Hematoxylin & Eosin 
staining display newly formed bone were cell nuclei are detected with blue 
colour. A-D show newly formed bone induced by cells seeded on a CopiOsTM 
carrier, A: Control 1, B: Control 2, C: N540K, D: G380R. E-H, display newly 
formed bone induced by cells seeded on CollagraftTM carrier, E: Control 1, 
F: Control 2, G: N540K, H: G380R. I, Show percentage of formed bone. 
Magnification: 100X, Scale bar: 100µm
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Figure 4: Correlation and prediction of in vivo bone formation with in 
vitro factors. Empirical modelling was carried out to find the combination of 
in vitro factors that are predictive of ectopic in vivo bone formation. A: in vitro 
and in vivo measurements clustered according to their pairwise correlations. 
B: variable importance plot generated by a first partial least square regression 
(PLSR) model including all in vitro measurements. Only variables with a 
importance larger than 0.8 (underlined) have been retained for the final PLSR 
model. C: Results of the final PLSR model showing the predicted versus 
measured (‘actual’) values (top) for the percent of bone formed in vivo in 
CopiosTM (left) and CollagraftTM (right) carriers. The bottom row shows the 
difference between measured and predicted values. Symbols are defined as 
follows: □: control 1; ◊: control 2; ∆: N540K; o: G380R.
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osteocalcin in N540K cells. Together, these represent early to fully 
differentiated osteoblasts [27,28].
Empirical modelling showed that in vivo bone forming capacity 
can be predicted by the in vitro level of phosphorylation of Erk1/2, 
metabolic activity, ALP, Coll1 and osteocalcin expression. In the case 
of N540K, increased levels of these in vitro measures correspond to the 
elevated in vivo bone forming capacity. Proliferative ability of the cells 
has previously been determined to strongly correlate to in vivo bone 
forming capacity of bone marrow stromal cells [29]. Additionally, Coll1 
expression was previously correlated to the bone forming capacity 
of PDCs [12,30]. This together strengthens the predictive model in 
this study, which indicates that proliferation along with accelerated 
osteogenic differentiation may be involved with the phenomenon 
observed with PDCs containing the N540K mutation in FGFR3. We 
propose that the specific profile shown in the N540K mutant is due to 
the intracellular location of this mutation, leading to a ligand-binding 
independent constitutively active receptor, which becomes internalised 
upon phosphorylation, and consequently a termination of induced 
signalling. 
This study indicates the importance of FRFG3 signalling in 
periosteal cell dynamics and indicates a possible cause of increased 
bone density with some mutations. Additionally, we suggest a potential 
mechanism for periosteal cell manipulation to enhance bone formation 
for tissue engineering applications.
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